Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 17/20 | 0.36 |
| ▸ | MAOB | P27338 | 8/20 | 0.36 |
| ▸ | MAOA | P21397 | 5/20 | 0.36 |
| ▸ | KDM1B | Q8NB78 | 2/20 | 0.36 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL955079 | 1.00 | KDM1A (0.36) | KDM1AMAOBMAOAKDM1BRCOR1 | |
| Hydrochloric Acid SCHEMBL30556192 | 0.98 | KDM1A (0.38) | KDM1AMAOBMAOAKDM1BRCOR1 | |
| SCHEMBL2405510 | 0.87 | ALDH1A1 (0.42) | KDM1AMAOBMAOAALDH1A1HSD17B10 | |
| SCHEMBL19366623 | 0.84 | ALDH1A1 (0.44) | KDM1AMAOBMAOAKDM1BRCOR1 | |
| SCHEMBL20907336 | 0.84 | ALDH1A1 (0.44) | KDM1AMAOBMAOAKDM1BRCOR1 | |
| SCHEMBL933210 | 0.84 | ALDH1A1 (0.44) | KDM1AMAOBMAOAKDM1BRCOR1 | |
| SCHEMBL21422778 | 0.84 | ALDH1A1 (0.44) | KDM1AMAOBMAOAALDH1A1HSD17B10 | |
| Trifluoroacetic Acid SCHEMBL1811903 | 0.82 | ROCK2 (0.34) | KDM1AMAOBMAOAKDM1BRCOR1 | |
| SCHEMBL1459410 | 0.81 | ALDH1A1 (0.42) | KDM1AMAOBMAOAKDM1BRCOR1 | |
| SCHEMBL9760083 | 0.78 | TTR (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322792-A1 | CDK9 INHIBITORS | BAERENKRAFT THERAPEUTICS, LLC | 2023-10-12 | — | — | US | disclosed |
| US-20230322792-A1 | CDK9 INHIBITORS | BAERENKRAFT THERAPEUTICS, LLC | 2023-10-12 | — | — | US | disclosed |
| WO-2023196517-A1 | CDK9 INHIBITORS | Biolexis Therapeutics, Inc. (US) | 2023-10-12 | — | — | WO | disclosed |
| US-20230065740-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | SPV THERAPEUTICS INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230048132-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | SPV THERAPEUTICS INC. | 2023-02-16 | — | — | US | disclosed |
| US-20220220103-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | SPV THERAPEUTICS INC. | 2022-07-14 | — | — | US | disclosed |
| WO-2022111634-A1 | HETEROARYLQUINAZOLINE COMPOUNDS AS PROTEIN KINASE INHIBITORS | 成都赛璟生物医药科技有限公司 | 2022-06-02 | — | — | WO | disclosed |
| US-20220056037-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | SPV THERAPEUTICS INC. | 2022-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322792-A1 | CDK9 INHIBITORS | CDK9, CDK19, CDK3 | KDM1A 623/4885MAOB 4038/4885MAOA 4548/4885 |
| US-20220056037-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | CDK2, CDK1, CCNK | KDM1A 1011/4885MAOB 3650/4885MAOA 4110/4885 |
| US-20230065740-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | CDK2, CDK1, CCNK | KDM1A 1011/4885MAOB 3650/4885MAOA 4110/4885 |
| US-20220220103-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | CDK2, CDK1, CCNK | KDM1A 1011/4885MAOB 3650/4885MAOA 4110/4885 |
| US-20230048132-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | CDK2, CDK1, CCNK | KDM1A 1011/4885MAOB 3650/4885MAOA 4110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.